Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLETE: mFOLFOXIRI + Panitumumab vs mFOLFOX6 + Panitumumab in RAS/BRAF WT mCRC
NCT03231722Phase 3Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Sep 2017
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (metastatic) (mCRC), sponsored by Gruppo Oncologico Nord Ovest. Started Sep 2017; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03231722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231722.